Bal Pharma Analyst Review 2027: Revenue Up 22% and Profit Doubles, but Debt Is Heavy
- November 20, 2026
- Posted by: Chaitanya Auti
- Category: Market
Bal Pharma Stock Snapshot (19 Nov 2026)
- Current Market Price (CMP): ₹84.61
- 52-Week High / Low: ₹124.60 / ₹60
- Market Capitalisation: ₹135 crore
- P/E Ratio vs Industry P/E: 16.9 vs 40.1
- Latest Quarter (Q2 FY27) Revenue: ₹89.95 crore
- Latest Quarter (Q2 FY27) Net Profit: ₹1.43 crore
Quick Answer: The Bal Pharma analyst review 2027 finds no brokerage coverage as of November 2026. Q2 FY27 consolidated revenue rose 21.5% to ₹89.95 crore, operating profit rose 51% to ₹8.66 crore and net profit nearly doubled to ₹1.43 crore from ₹0.72 crore. The stock closed at ₹84.61 on 19 November 2026, about 32% below its 52-week high, at about 17 times trailing earnings, which frames any Bal Pharma share price target 2027 view.
The Bal Pharma analyst review 2027 covers a Bengaluru-based drug maker that produces active pharmaceutical ingredients (APIs), finished formulations and a small range of Ayurvedic products for India and export markets. Readers searching for a Bal Pharma share price target 2027 will not find a named brokerage figure, so this review relies on results, margins and balance sheet trends.
Bal Pharma closed at ₹84.61 on 19 November 2026, about 32% below its 52-week high of ₹124.60 and about 41% above its low of ₹60. This Bal Pharma analyst review 2027 explains the quarter and what shapes the Bal Pharma stock outlook 2027.
Click Here – Get Free Investment Predictions
What Analysts Say in the Bal Pharma Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| No verified coverage | Not available | Not available | As of November 2026 |
No brokerage publishes a target on Bal Pharma. It is a small company worth about ₹135 crore with almost no institutional holding, which keeps it outside formal research.
Margins, debt and the API to formulation mix are the main reference points. This Bal Pharma analyst review 2027 uses them to judge whether the profit recovery can continue.
Q2 FY27 Results in the Bal Pharma Analyst Review 2027
| Metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Consolidated revenue | ₹89.95 crore | About ₹74 crore | Up 21.5% |
| Operating profit | ₹8.66 crore | ₹5.73 crore | Up 51.1% |
| Operating margin | About 9.6% | About 7.7% | Higher |
| Net profit | ₹1.43 crore | ₹0.72 crore | Nearly doubled |
| Q1 FY27 net profit | About ₹1.13 crore | Not applicable | Up about 27% QoQ |
Revenue growth was strong, and operating profit grew more than twice as fast as sales, which lifted margins. Standalone revenue from operations was about ₹89.7 crore, up about 21.6%.
Net profit is still small relative to sales, at under 2%, because interest and depreciation absorb most of the operating profit. In this Bal Pharma analyst review 2027, the high finance cost is the main reason profit stays thin even when revenue grows.
How Bal Pharma Makes Money
Bal Pharma earns revenue from two main businesses and a small third one.
- APIs: bulk drug ingredients sold to other drug makers, a little over half of revenue.
- Formulations: tablets, capsules and other finished medicines sold in India and abroad.
- Ayurveda: a small range of herbal products.
FY26 consolidated revenue was about ₹312 crore, up 2.8%, while net profit fell 12.7% to about ₹6.3 crore. Revenue has barely grown over three years, so the strong first half of FY27 is the main change in this Bal Pharma analyst review 2027.
The board recommended a dividend of ₹1.20 per share for FY26 and approved a preferential issue of warrants to promoters. If converted, the warrants would bring in fresh equity, which could help reduce debt.
Debt to equity is high at about 2.07, which makes the company sensitive to interest rates. Operating cash flow was steady at about ₹31 crore in FY26.
Many larger generic drug makers in the Nifty Pharma index earn far higher margins than Bal Pharma. API businesses in particular face strong price competition from China, which keeps margins under pressure for smaller producers.
The stock jumped about 20% in a single session in September 2026 before falling back, a sign of how sharply small pharma stocks can move on limited news.
Moving up the value chain matters for a company of this size. APIs are sold in bulk to other drug makers and often compete mainly on price, while branded or contract formulations can earn better margins and steadier orders. A higher share of formulations, along with lower interest costs, would be the clearest path to stronger profit for Bal Pharma over the next few years.
Growth Triggers in the Bal Pharma Analyst Review 2027
- Revenue growth: up 21.5% in Q2 FY27.
- Margin gain: operating margin up to about 9.6%.
- Promoter warrants: possible fresh equity to cut debt.
- Dividend: ₹1.20 per share for FY26, a yield near 1.4%.
- Export demand: formulation sales in export markets, relevant to any Bal Pharma share price target 2027 view.
Key Risks in the Bal Pharma Analyst Review 2027
- High debt: debt to equity of about 2.07.
- Thin net margin: under 2% in Q2.
- API pricing: competition from Chinese suppliers.
- Raw material costs: input price swings affect margins.
- Low liquidity: thin trading and sharp moves, a key point in the Bal Pharma analyst review 2027.
Compare Bal Pharma With Other Pharma Stocks on the Univest Screener
Bal Pharma Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (19 Nov 2026) | ₹84.61 |
| 52-Week High / Low | ₹124.60 / ₹60 |
| Market Capitalisation | About ₹135 crore |
| P/E (TTM) | About 16.9 |
| Industry P/E | About 40.1 |
| Return on Equity | About 9.1% |
| Debt to Equity | 2.07 |
| Dividend Yield | About 1.4% |
The P/E of about 17 is well below the industry level of about 40. In this Bal Pharma analyst review 2027, the discount reflects high debt, thin net margins and slow growth in past years, while the recent pickup in revenue argues for a closer look.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 50.86% | 50.86% | No change |
| Foreign Investors (FII) | 0.22% | 0.28% | Up 0.06 pts |
| Domestic Institutions (DII) | 0.00% | 0.00% | No change |
| Public | 48.92% | 48.87% | Down 0.05 pts |
Managing Director Shailesh Siroya holds 17.24%, and Micro Labs Limited holds 12.64%. The promoter stake was unchanged over the year, and the Bal Pharma analyst review 2027 notes that the planned warrant issue could lift it if converted.
What to Watch After the Bal Pharma Analyst Review 2027
- Margins: whether operating margin stays near 10%.
- Debt: use of warrant money to reduce borrowings.
- API prices: competition and input costs.
- Exports: growth in formulation exports.
- Coverage: any research that sets a Bal Pharma share price target 2027.
Final Word on the Bal Pharma Analyst Review 2027
The Bal Pharma analyst review 2027 shows faster revenue growth, better margins and a profit that nearly doubled in Q2. Debt is high, net margin is thin and the stock moves sharply on small volumes.
The Bal Pharma stock outlook 2027 depends on margin gains, debt reduction and steady demand for APIs and formulations. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Bal Pharma analyst review 2027 show?
It shows faster growth, with Q2 FY27 consolidated revenue up 21.5% to ₹89.95 crore and operating profit up 51% to ₹8.66 crore. Net profit nearly doubled to ₹1.43 crore from ₹0.72 crore. Operating margin improved to about 9.6%.
Is there a Bal Pharma share price target 2027 from brokerages?
No named brokerage target exists as of November 2026. The stock closed at ₹84.61 on 19 November 2026, about 32% below its 52-week high of ₹124.60. Results and debt levels are the main reference points.
What does Bal Pharma make?
Bal Pharma makes active pharmaceutical ingredients, finished formulations and a small range of Ayurvedic products. APIs make up a little over half of revenue. It sells in India and export markets.
Why is Bal Pharma’s net profit so small?
Interest and depreciation absorb most of the operating profit. Debt to equity is high at about 2.07. Net margin was under 2% in Q2 FY27 even after the jump in profit.
Is Bal Pharma stock undervalued based on the Bal Pharma analyst review 2027?
The stock trades at about 17 times earnings, below the industry P/E of about 40. Return on equity is about 9.1% and the dividend yield is about 1.4%. High debt and thin margins explain much of the discount.
Who owns Bal Pharma?
Promoters hold 50.86%, with Managing Director Shailesh Siroya at 17.24%. Micro Labs Limited holds 12.64%. Public shareholders hold 48.87%.
What should investors watch after the Bal Pharma analyst review 2027?
Watch whether operating margin stays near 10% and whether the warrant money cuts debt. Track API pricing and export growth. Any research coverage would add a fresh reference point.